OpenAlex
PricingAboutJobs
Log inGet started
Work

ABCL-1390: Addition of Fixed Low-Dose Nivolumab to R-DAEPOCH Is Associated With Improved Event-Free Survival in Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

HTML

Year: 2026
Type: article
Study design: Observational Study
Source: Clinical Lymphoma Myeloma & Leukemia
DOI: 10.1016/s2152-2650(26)02640-6
Authors: Runiza Abdurashidova, Yana Mangasarova, Elena Baryakh, Natalia Mikhaylova, Hunan Julhakyan, Tanzila Ushaeva, Aminat Magomedova, Anna Kravtsova, Raisa Dorzhieva, Daria Belkina, Ekaterina Fastova, Ekaterina Gitelzon, Oleg Margolin, Madina Bagova, Inna Krasilnikova, Evgeny Zvonkov, Elena Parovichnikova
Institution: National Medical Research Center for Hematology
Language: English

Topic: Lymphoma Diagnosis and Treatment
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Keywords: B-cell lymphoma, nivolumab, DA-EPOCH-R, first-line therapy, immune checkpoint inhibitors, event-free survival, newly diagnosed lymphoma, treatment toxicity, Deauville score, PET/CT response assessment, relapse-free survival, non-relapse mortality, immune-related adverse events, relapsed/refractory lymphoma
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W7204706113
FWCI:
Cites:
Cited by:
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms